Earnings Call Summary | Predictive Oncology(POAI.US) Q1 2024 Earnings Conference
Earnings Call Summary | Predictive Oncology(POAI.US) Q1 2024 Earnings Conference
The following is a summary of the Predictive Oncology Inc. (POAI) Q1 2024 Earnings Call Transcript:
以下是預測腫瘤學公司（POAI）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Predictive Oncology concluded Q1 2024 with $5.2 million cash and $4.0 million in stockholders' equity.
The net loss per share for the quarter was $1.04 per basic and diluted share compared to $0.86 for the same period in 2023.
The company reported revenues of $420,000 for the first quarter of 2024, an increase from the $240,000 in Q1 2023.
預測腫瘤學在2024年第一季度結束時擁有520萬澳元的現金和400萬澳元的股東權益。
本季度每股淨虧損爲每股基本和攤薄後每股虧損1.04美元，而2023年同期爲0.86美元。
該公司報告稱，2024年第一季度的收入爲42萬美元，較2023年第一季度的24萬美元有所增加。
Business Progress:
業務進展：
Significant progress was made in a study using Predictive Oncology's AI capabilities to improve survival rates in ovarian cancer patients.
Collaborations with Fujifilm and Cvergenx have been announced.
The FluGen project for an intranasal flu vaccine is advancing with the support of a $6.2 million Phase 2b grant by the US Department of Defense.
A new at-the-market financing instrument has also been established, allowing for the sale of common shares periodically.
一項利用預測腫瘤學的人工智能能力提高卵巢癌患者存活率的研究取得了重大進展。
已經宣佈了與富士膠片和Cvergenx的合作。
在美國國防部620萬美元的第二階段撥款的支持下，FluGen鼻內流感疫苗項目正在推進中。
還建立了一種新的市場融資工具，允許定期出售普通股。
More details: Predictive Oncology IR
更多詳情： 預測性腫瘤學 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。